Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
59
PRQR Quote, Financials, Valuation and Earnings
Last price:
$2.19
Seasonality move
:
13.33%
Day range:
$2.15 - $2.21
52-week range:
$1.07 - $3.10
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
13.13x
P/B ratio:
3.41x
Volume:
144.8K
Avg. volume:
524K
1-year change:
-18.73%
Market cap:
$228.6M
Revenue:
$20.4M
EPS (TTM):
-$0.46
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PRQR
ProQR Therapeutics NV
|
$7M | -$0.17 | 32.53% | -55.96% | $8.88 |
|
ARGX
argenx SE
|
$1.1B | $4.11 | 87.13% | 205.62% | $1,010.28 |
|
MRUS
Merus NV
|
$8.7M | -$1.36 | -7.07% | -135.86% | $97.00 |
|
PHAR
Pharming Group NV
|
$91.2M | $0.00 | 11.23% | -90.74% | $31.00 |
|
PHVS
Pharvaris NV
|
-- | -$0.78 | -- | -4.68% | $46.01 |
|
QURE
uniQure NV
|
$5.2M | -$0.86 | 8.51% | -38.17% | $55.30 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PRQR
ProQR Therapeutics NV
|
$2.17 | $8.88 | $228.6M | -- | $0.00 | 0% | 13.13x |
|
ARGX
argenx SE
|
$848.48 | $1,010.28 | $52.2B | 43.13x | $0.00 | 0% | 18.10x |
|
MRUS
Merus NV
|
$96.91 | $97.00 | $7.4B | -- | $0.00 | 0% | 121.82x |
|
PHAR
Pharming Group NV
|
$18.09 | $31.00 | $1.2B | 1,265.04x | $0.00 | 0% | 3.41x |
|
PHVS
Pharvaris NV
|
$25.93 | $46.01 | $1.7B | -- | $0.00 | 0% | -- |
|
QURE
uniQure NV
|
$25.19 | $55.30 | $1.6B | -- | $0.00 | 0% | 86.07x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PRQR
ProQR Therapeutics NV
|
20.36% | 3.523 | 7.64% | 3.23x |
|
ARGX
argenx SE
|
-- | 0.059 | -- | 4.92x |
|
MRUS
Merus NV
|
1.57% | 2.127 | 0.17% | 7.55x |
|
PHAR
Pharming Group NV
|
33.1% | -0.371 | 13.18% | 2.39x |
|
PHVS
Pharvaris NV
|
0.19% | 0.173 | 0.04% | 12.56x |
|
QURE
uniQure NV
|
69.92% | 0.547 | 14.65% | 6.94x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PRQR
ProQR Therapeutics NV
|
$2.6M | -$13.2M | -54.22% | -67.34% | -392.68% | -$15.4M |
|
ARGX
argenx SE
|
$837.2M | $203.8M | 24.23% | 28.06% | 30.38% | $312.8M |
|
MRUS
Merus NV
|
$11.5M | -$96.5M | -52.67% | -53.47% | -794.06% | -$90.4M |
|
PHAR
Pharming Group NV
|
$89.8M | $15.8M | 0.25% | 0.39% | 16.34% | $29.9M |
|
PHVS
Pharvaris NV
|
-$122.9K | -$46.3M | -62.86% | -63% | -- | -$38.2M |
|
QURE
uniQure NV
|
-$329K | -$50.7M | -40.98% | -382.35% | -1370.5% | -$17.7M |
ProQR Therapeutics NV vs. Competitors
-
Which has Higher Returns PRQR or ARGX?
argenx SE has a net margin of -381.88% compared to ProQR Therapeutics NV's net margin of 25.88%. ProQR Therapeutics NV's return on equity of -67.34% beat argenx SE's return on equity of 28.06%.
Company Gross Margin Earnings Per Share Invested Capital PRQRProQR Therapeutics NV76.72% -$0.12 $84.2M ARGXargenx SE88.32% $3.74 $6.1B -
What do Analysts Say About PRQR or ARGX?
ProQR Therapeutics NV has a consensus price target of $8.88, signalling upside risk potential of 308.99%. On the other hand argenx SE has an analysts' consensus of $1,010.28 which suggests that it could grow by 19.38%. Given that ProQR Therapeutics NV has higher upside potential than argenx SE, analysts believe ProQR Therapeutics NV is more attractive than argenx SE.
Company Buy Ratings Hold Ratings Sell Ratings PRQRProQR Therapeutics NV7 0 0 ARGXargenx SE15 2 0 -
Is PRQR or ARGX More Risky?
ProQR Therapeutics NV has a beta of 0.176, which suggesting that the stock is 82.397% less volatile than S&P 500. In comparison argenx SE has a beta of 0.366, suggesting its less volatile than the S&P 500 by 63.397%.
-
Which is a Better Dividend Stock PRQR or ARGX?
ProQR Therapeutics NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. argenx SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProQR Therapeutics NV pays -- of its earnings as a dividend. argenx SE pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRQR or ARGX?
ProQR Therapeutics NV quarterly revenues are $3.4M, which are smaller than argenx SE quarterly revenues of $948M. ProQR Therapeutics NV's net income of -$12.9M is lower than argenx SE's net income of $245.4M. Notably, ProQR Therapeutics NV's price-to-earnings ratio is -- while argenx SE's PE ratio is 43.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProQR Therapeutics NV is 13.13x versus 18.10x for argenx SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRQRProQR Therapeutics NV13.13x -- $3.4M -$12.9M ARGXargenx SE18.10x 43.13x $948M $245.4M
-
Which has Higher Returns PRQR or MRUS?
Merus NV has a net margin of -381.88% compared to ProQR Therapeutics NV's net margin of -786.17%. ProQR Therapeutics NV's return on equity of -67.34% beat Merus NV's return on equity of -53.47%.
Company Gross Margin Earnings Per Share Invested Capital PRQRProQR Therapeutics NV76.72% -$0.12 $84.2M MRUSMerus NV94.71% -$1.26 $787.2M -
What do Analysts Say About PRQR or MRUS?
ProQR Therapeutics NV has a consensus price target of $8.88, signalling upside risk potential of 308.99%. On the other hand Merus NV has an analysts' consensus of $97.00 which suggests that it could grow by 0.09%. Given that ProQR Therapeutics NV has higher upside potential than Merus NV, analysts believe ProQR Therapeutics NV is more attractive than Merus NV.
Company Buy Ratings Hold Ratings Sell Ratings PRQRProQR Therapeutics NV7 0 0 MRUSMerus NV2 13 0 -
Is PRQR or MRUS More Risky?
ProQR Therapeutics NV has a beta of 0.176, which suggesting that the stock is 82.397% less volatile than S&P 500. In comparison Merus NV has a beta of 1.061, suggesting its more volatile than the S&P 500 by 6.069%.
-
Which is a Better Dividend Stock PRQR or MRUS?
ProQR Therapeutics NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merus NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProQR Therapeutics NV pays -- of its earnings as a dividend. Merus NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRQR or MRUS?
ProQR Therapeutics NV quarterly revenues are $3.4M, which are smaller than Merus NV quarterly revenues of $12.2M. ProQR Therapeutics NV's net income of -$12.9M is higher than Merus NV's net income of -$95.5M. Notably, ProQR Therapeutics NV's price-to-earnings ratio is -- while Merus NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProQR Therapeutics NV is 13.13x versus 121.82x for Merus NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRQRProQR Therapeutics NV13.13x -- $3.4M -$12.9M MRUSMerus NV121.82x -- $12.2M -$95.5M
-
Which has Higher Returns PRQR or PHAR?
Pharming Group NV has a net margin of -381.88% compared to ProQR Therapeutics NV's net margin of 7.71%. ProQR Therapeutics NV's return on equity of -67.34% beat Pharming Group NV's return on equity of 0.39%.
Company Gross Margin Earnings Per Share Invested Capital PRQRProQR Therapeutics NV76.72% -$0.12 $84.2M PHARPharming Group NV92.7% $0.11 $395.6M -
What do Analysts Say About PRQR or PHAR?
ProQR Therapeutics NV has a consensus price target of $8.88, signalling upside risk potential of 308.99%. On the other hand Pharming Group NV has an analysts' consensus of $31.00 which suggests that it could grow by 71.37%. Given that ProQR Therapeutics NV has higher upside potential than Pharming Group NV, analysts believe ProQR Therapeutics NV is more attractive than Pharming Group NV.
Company Buy Ratings Hold Ratings Sell Ratings PRQRProQR Therapeutics NV7 0 0 PHARPharming Group NV2 0 0 -
Is PRQR or PHAR More Risky?
ProQR Therapeutics NV has a beta of 0.176, which suggesting that the stock is 82.397% less volatile than S&P 500. In comparison Pharming Group NV has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock PRQR or PHAR?
ProQR Therapeutics NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pharming Group NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProQR Therapeutics NV pays -- of its earnings as a dividend. Pharming Group NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRQR or PHAR?
ProQR Therapeutics NV quarterly revenues are $3.4M, which are smaller than Pharming Group NV quarterly revenues of $96.9M. ProQR Therapeutics NV's net income of -$12.9M is lower than Pharming Group NV's net income of $7.5M. Notably, ProQR Therapeutics NV's price-to-earnings ratio is -- while Pharming Group NV's PE ratio is 1,265.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProQR Therapeutics NV is 13.13x versus 3.41x for Pharming Group NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRQRProQR Therapeutics NV13.13x -- $3.4M -$12.9M PHARPharming Group NV3.41x 1,265.04x $96.9M $7.5M
-
Which has Higher Returns PRQR or PHVS?
Pharvaris NV has a net margin of -381.88% compared to ProQR Therapeutics NV's net margin of --. ProQR Therapeutics NV's return on equity of -67.34% beat Pharvaris NV's return on equity of -63%.
Company Gross Margin Earnings Per Share Invested Capital PRQRProQR Therapeutics NV76.72% -$0.12 $84.2M PHVSPharvaris NV-- -$0.70 $367.6M -
What do Analysts Say About PRQR or PHVS?
ProQR Therapeutics NV has a consensus price target of $8.88, signalling upside risk potential of 308.99%. On the other hand Pharvaris NV has an analysts' consensus of $46.01 which suggests that it could grow by 77.43%. Given that ProQR Therapeutics NV has higher upside potential than Pharvaris NV, analysts believe ProQR Therapeutics NV is more attractive than Pharvaris NV.
Company Buy Ratings Hold Ratings Sell Ratings PRQRProQR Therapeutics NV7 0 0 PHVSPharvaris NV8 1 0 -
Is PRQR or PHVS More Risky?
ProQR Therapeutics NV has a beta of 0.176, which suggesting that the stock is 82.397% less volatile than S&P 500. In comparison Pharvaris NV has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock PRQR or PHVS?
ProQR Therapeutics NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pharvaris NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProQR Therapeutics NV pays -- of its earnings as a dividend. Pharvaris NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRQR or PHVS?
ProQR Therapeutics NV quarterly revenues are $3.4M, which are larger than Pharvaris NV quarterly revenues of --. ProQR Therapeutics NV's net income of -$12.9M is higher than Pharvaris NV's net income of -$43.4M. Notably, ProQR Therapeutics NV's price-to-earnings ratio is -- while Pharvaris NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProQR Therapeutics NV is 13.13x versus -- for Pharvaris NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRQRProQR Therapeutics NV13.13x -- $3.4M -$12.9M PHVSPharvaris NV-- -- -- -$43.4M
-
Which has Higher Returns PRQR or QURE?
uniQure NV has a net margin of -381.88% compared to ProQR Therapeutics NV's net margin of -2175.87%. ProQR Therapeutics NV's return on equity of -67.34% beat uniQure NV's return on equity of -382.35%.
Company Gross Margin Earnings Per Share Invested Capital PRQRProQR Therapeutics NV76.72% -$0.12 $84.2M QUREuniQure NV-8.89% -$1.38 $760.4M -
What do Analysts Say About PRQR or QURE?
ProQR Therapeutics NV has a consensus price target of $8.88, signalling upside risk potential of 308.99%. On the other hand uniQure NV has an analysts' consensus of $55.30 which suggests that it could grow by 119.54%. Given that ProQR Therapeutics NV has higher upside potential than uniQure NV, analysts believe ProQR Therapeutics NV is more attractive than uniQure NV.
Company Buy Ratings Hold Ratings Sell Ratings PRQRProQR Therapeutics NV7 0 0 QUREuniQure NV9 2 0 -
Is PRQR or QURE More Risky?
ProQR Therapeutics NV has a beta of 0.176, which suggesting that the stock is 82.397% less volatile than S&P 500. In comparison uniQure NV has a beta of 0.586, suggesting its less volatile than the S&P 500 by 41.431%.
-
Which is a Better Dividend Stock PRQR or QURE?
ProQR Therapeutics NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. uniQure NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProQR Therapeutics NV pays -- of its earnings as a dividend. uniQure NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRQR or QURE?
ProQR Therapeutics NV quarterly revenues are $3.4M, which are smaller than uniQure NV quarterly revenues of $3.7M. ProQR Therapeutics NV's net income of -$12.9M is higher than uniQure NV's net income of -$80.5M. Notably, ProQR Therapeutics NV's price-to-earnings ratio is -- while uniQure NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProQR Therapeutics NV is 13.13x versus 86.07x for uniQure NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRQRProQR Therapeutics NV13.13x -- $3.4M -$12.9M QUREuniQure NV86.07x -- $3.7M -$80.5M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
